Biosfer Teslab Collaborates in Cancer Studies
Metabolomics can help in the study of different cancers by analysing whether a particular type of tumour is characterised by the development of certain metabolites. To this aim, Biosfer Teslab collaborates directly with Josep Gumà, director of the Oncology Institute of Southern Catalonia, and together with the Higher Technical School of Engineering of the URV […]
Early molecular signature of Parkinson and dementia years before the diseases appear
NMR metabolomics could identify altered lipoprotein and protein glycosylation profiles in REM sleep behavior disorder (iRBD), the prodromal stage of Lewy-type synucleinopathies (LTS) -including Parkinson and dementia. NMR showed predictive power distinguishing future clinical outcome, being a useful tool for identifying short-term high-risk patients for conversion to parkinsonism or dementia. Here you can see the […]
The use of Liposcale® Test in Premature Cardiovascular disease
Last week, a new paper, which evaluates the use of the Liposcale® test as a predictor of premature cardiovascular disease (PRESARV-SEA Study), was published. Beyond levels of LDL-C, results reported in the article support the relevance of LDL cholesterol composition and size on premature cardiovascular disease progression and its potential as a new biomarker for […]
Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia
Dr. Amor and collaborators have published a new article in the Diabetes Research and Clinical Practice journal using our plasma metabolomics analysis. The aim of the study was to evaluate the role of plasma metabolomics in atherosclerosis according to the presence of type 1 diabetes (T1D) or previous preeclampsia. They have concluded that plasma metabolomics […]
Biosfer Teslab’s Internacionalization
Biosfer Teslab has received from the Cambra de comerç de Reus an Xpande Digital 2020: a competitive call for international digitization! This action is co-financed with FEDER funds (European Regional Development Fund) from the European Union. This call is aimed to support the digitization of SMEs, as part of its international strategy, whose main objective […]
Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy
Abstract The sizes of certain types of lipoprotein particles have been associated with an increased risk of cardiovascular disease. However, there is currently no gold standard technique for the determination of this parameter. Here, we propose an analytical procedure to measure lipoprotein particles sizes using diffusion-ordered nuclear magnetic resonance spectroscopy (DOSY). The method was tested […]
Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for the characterisation of human plasma lipoproteins
Abstract Determining the concentration and size of lipoprotein complexes is very important due to their role in cardiovascular diseases and metabolic disorders. However, standard methods for lipoprotein fractionation are manual and time consuming and cannot be used as standard diagnostic tools. Because different subclasses of lipoproteins have different radii and, hence, different diffusion velocities, we […]
From LAB to market
Last year we published 19 scientific articles in international journals. We are a metabolomics company halfway between research and clinical practice, a scientific research group in a business environment that is committed to translational research. We carry out scientific collaborations with research groups from universities, research institutions, hospitals and companies in the biomedical sector both […]
Biosfer was awarded with the INNOWWIDE: a high competitive European call
Recently our CEO, Núria Amigó, was invited to participate in the first INNOWWIDE Focus Group, a virtual meeting organized by Steinbeis 2i innovative + international, as an INNOWWIDE funding recipient representative, to evaluate the call impact and to get insight the entire process, enabling to see those activities which we were good at and those […]
GlycA as a new biomarker in rheumatoid arthritis
The research group in Immunology at the University of Oviedo with the participation of Dr. Javier Rodríguez-Carrio has published a study in which one of the variables from our glycoprotein test has been identified as an emerging biomarker for stratification and decision-making in early-stage rheumatoid arthritis. If you want to know more about this publication, […]
